Cost-effectiveness analysis of rivaroxaban for treatment and secondary prevention of venous thromboembolism in the Netherlands. [electronic resource]
Producer: 20180507Description: 813-824 p. digitalISSN:- 1941-837X
- Anticoagulants -- administration & dosage
- Cost-Benefit Analysis
- Female
- Health Resources -- economics
- Hemorrhage -- chemically induced
- Heparin, Low-Molecular-Weight -- administration & dosage
- Humans
- Male
- Markov Chains
- Middle Aged
- Models, Econometric
- Netherlands
- Quality-Adjusted Life Years
- Rivaroxaban -- administration & dosage
- Secondary Prevention
- Venous Thromboembolism -- prevention & control
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.